Spatially resolved whole-transcriptomic profiling of EGFR-mutated lung adenocarcinomas stratified by PD-L1 expression
Cellular Oncology · 2025
DOI: 10.1007/s13402-025-01143-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2025. Verfasst von Chenxi Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Adenocarcinoma of Lung, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Suzhou Basic Research Program, the Project of Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology.
Abstract (Originalsprache)
PURPOSE: High programmed death-ligand 1 (PD-L1) expression is associated with unfavorable clinical outcomes in epidermal growth factor receptor (EGFR)-mutated lung adenocarcinomas (LUAD) patients treated with tyrosine kinase inhibitors (TKIs) or anti-PD-1/PD-L1 therapy, yet the underlying mechanisms are less explored. METHODS: Bulk RNA sequencing (RNA-seq) datasets were analyzed to investigate intertumoral transcriptional variations linked to PD-L1 expression. Immunohistochemistry (IHC) was utilized to quantify PD-L1 expression on tumor cells. Digital spatial profiling (DSP) was performed on 23 EGFR-mutated LUAD tissue samples to characterize transcriptomic differences in tumor cell (TC), immune cell (IM), and macrophage (MA) compartments between PD-L1 high and low groups. Furthermore, a publicly available DSP dataset was analyzed and IHC was conducted for validation. RESULTS: Analysis of RNA-seq datasets identified differentially expressed genes, signaling pathways, and immune profiles associated with PD-L1 expression. Compared to low PD-L1 tumors, high PD-L1 tumors exhibited increased infiltration of T regulatory cells (Tregs) and enhanced immunosuppressive signatures. DSP analysis revealed compartment-specific molecular disparities: TC segment in high PD-L1 tumors showed upregulated signatures of cell proliferation, invasion, and metastasis. IM segment displayed increased infiltration of immunosuppressive cells, including Tregs and myeloid-derived suppressor cells and upregulated expression of inhibitory immunomodulators CD276, HAVCR2, and LGALS9C. CONCLUSION: Combining bulk and spatial RNA-seq, this study characterized the molecular and immunological hallmarks of EGFR-mutated LUAD in the context of PD-L1 expression, providing new insights into the development of tailored therapeutic strategies for EGFR-mutated LUAD with high PD-L1 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
- Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
- Department of Thoracic Surgery, Guanyun County People's Hospital, Lianyungang, 222500, China.
- Department of Life Science, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, 999077, China.
- Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology, Suzhou Vocational Health College, Suzhou, 215009, China.
- Department of Biostatistics, School of Public Health, Suzhou Medical College of Soochow University, Suzhou, 215123, China.
Förderung
- Suzhou Basic Research Program
- the Project of Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology
Zitieren
APA
Yu, C., Shi, C., Zhou, H., Li, N., Ma, R., Liu, S., Tang, Z., Zhang, X., Lei, Z., & Qin, H. (2025). Spatially resolved whole-transcriptomic profiling of EGFR-mutated lung adenocarcinomas stratified by PD-L1 expression. Cellular Oncology. https://doi.org/10.1007/s13402-025-01143-9
Vancouver
Yu C, Shi C, Zhou H, Li N, Ma R, Liu S, et al. Spatially resolved whole-transcriptomic profiling of EGFR-mutated lung adenocarcinomas stratified by PD-L1 expression. Cellular Oncology. 2025. doi:10.1007/s13402-025-01143-9
BibTeX
@article{Yu2025,
author = {Yu, Chenxi and Shi, Chenxi and Zhou, Hao and Li, Na and Ma, Ruyi and Liu, SongBai and Tang, Zaixiang and Zhang, Xianling and Lei, Zhe and Qin, Hualong},
title = {Spatially resolved whole-transcriptomic profiling of EGFR-mutated lung adenocarcinomas stratified by PD-L1 expression},
journal = {Cellular Oncology},
year = {2025},
doi = {10.1007/s13402-025-01143-9}
}
EUVIMED